EyePoint, Inc.

EYPT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management4.7%Feb 14, 2025

SC 13G/ARA Capital Management6.1%Feb 14, 2024

SC 13G/A

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 2,468,314Value: $45.1M

# Signal Note: OrbiMed Initiates $45.1M Position in EyePoint OrbiMed's new 2.5M share stake signals conviction in EyePoint's sustained-release ocular portfolio, likely anchored on YUTIQ (fluocinolone acetonide implant) for non-infectious uveitis, which generated ~$37M in 2023 revenue with demonstrated label expansion potential. The timing suggests confidence in near-term catalysts, potentially including further geographic expansion, additional indication approvals, or improved reimbursement trajectory for the company's depot-based delivery platform.

Rock Springs CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS2 funds NBIX2 funds APLS2 funds FOLD2 funds BCAX2 funds ARGX2 funds OCUL2 funds JANX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Rock Springs Capital Initiates EyePoint Position** Rock Springs' $4.7M entry into EYPT likely reflects conviction in the company's ophthalmology pipeline, particularly YUTIQ (fluocinolone acetonide implant) for non-infectious uveitis, which achieved FDA approval in October 2021 and is ramping commercialization. The timing suggests confidence in near-term revenue inflection and potential label expansions or additional indications under development. As a concentrated healthcare specialist, Rock Springs' initiation signals they see catalysts outweighing current valuation risks.